Last reviewed · How we verify
NCT02526173
DHACM in Robotic Assisted Laparoscopic Prostatectomy (RALP)
NA trial testing RALP using full nerve sparing technique in Erectile Dysfunction in 230 participants. Completed in 21 June 2018.
21 June 2018
Quick facts
| Lead sponsor | MiMedx Group, Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 230 |
| Start date | 1 October 2015 |
| Primary completion | 21 June 2018 |
| Estimated completion | 21 June 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- RALP using full nerve sparing technique
- dHACM Application
Conditions studied
- Erectile Dysfunction — all drugs for Erectile Dysfunction →
Sponsor
MiMedx Group, Inc. — full company profile →
Who can join
Adults 40 to 70, male only, with Erectile Dysfunction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators will examine the beneficial impacts of applying of dHACM on the preserved neurovascular bundles (cavernosal nerves) and the prostate bed during robotic assisted laparoscopic prostatectomy. Such application can result in promotion of soft tissue healing and reduction of inflammation at the operative site and thus an acceleration of return of potency regulating cavernosal nerves.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02526173
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Erectile Dysfunction
Currently open trials in the same condition.
- NCT07442396 — The Effectiveness of Exercise in the Treatment of Erectile Dysfunction and Premature Ejaculation · NA · recruiting
- NCT07366970 — Is There a Benefit From Addition of Exercise in Diabetic Patients With ED Who Complain Low Vitamin D? · NA · recruiting
- NCT06960746 — Changing Lifestyle in OSA Males Who Suffer Metabolic Syndrome and Impotence: Is There a Response? · NA · recruiting
- NCT06872866 — The Objective of This Phase 1 Study is to Evaluate the Food Effect of 100 mg Hezkue Turbo® (ASP-001.1, Sildenafil) Under · Phase 1 · recruiting
- NCT06805513 — Actual Use Trial of Tadalafil 5 mg · Phase 3 · recruiting
Other MiMedx Group, Inc. trials
Trials by the same sponsor.
- NCT05796765 — Phase 2B Micronized DHACM vs. Saline in the Treatment of Knee Osteoarthritis · Phase 2 · terminated
- NCT03485157 — Micronized dHACM vs. Saline in the Treatment of Osteoarthritis of the Knee · Phase 2 · completed
- NCT03479463 — Use of Human Dehydrated Amnion Chorion Allograft in Laryngectomy/Pharyngectomy · terminated
- NCT03479489 — Use of Human Dehydrated Amnion Chorion Allograft in Closed Hemorroidectomy · NA · completed
- NCT03414255 — Micronized dHACM Injectable for the Treatment of Achille Tendonitis · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02526173 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by MiMedx Group, Inc.
- Last refreshed: 28 September 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02526173.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing